

tgcBIOMICS GmbH

Simon Koerpert – Manager Business Development

Carl-Zeiss-Strasse 51

D-55129 Mainz

Tel: +49 6131-62757-0

Fax: +49 6131 62757-18,

Email: s.koerpert@tgcBIOMICS.de

Homepage: www.tgcBIOMICS.de

CEO: Prof. Dr. von Eichel-Streiber

Founded in 1999

12 employees

tgcBIOMICS

tgcBIOMICS is the leading company of the new gene carrier technology to be used for the development of new drugs, therapeutics, vaccines and diagnostics.

tgcBIOMICS develops and produces new targets for pharmaceuticals / diagnostics and offers a broad spectrum of contract research & development opportunities in the biotechnology market. In general tgcBiomics handle unique services for the genomics and proteomics in the Life Sciences Industry. Main focus are diseases associated with Clostridium difficile (CDAD).

Fields of use:

- Pharma: new therapeutic entities (NTE), active pharmaceutical ingredients (API), pharmaceutical generics, active or passive vaccines
- Diagnostics: cancer, immunology and infectious diseases, developing high quality assay components like recombinant proteins and polyclonal/monoclonal tailor-made antibodies

Offer

Research & Development projects in

- biomarkers
- recombinant proteins and antibodies,
- vaccine design
- personalized medicine
- stem cell detection technology
- vaccines and therapeutics against Clostridium difficile infections

Request

- Partnering with pharmaceutical and diagnostic organizations
- European Funding partnerships
- VC investments

Type of Cooperation:

- Services and Contract Research & Diagnostic Product Development
- Technology Provider for diagnostics and therapeutics
- International partnership with Biotech Companies
- Fee-for-Service Projects, Feasibility studies